This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poorrisk CLM not selected for upfront resection. Patients and methods: Poor-risk CLM was defined as follows: more than four metastases, diameter >5 cm, R0 resection unlikely, inadequate viable liver function if undergoing upfront resection, inability to retain liver vascular supply, or synchronous colorectal primary presentation. Patients underwent baseline computed tomography, magnetic resonance imaging, and/or positron emission tomography (PET) for staging and received neoadjuvant CAPOX plus bevacizumab, with resectability assessed every four cycles. Primary end point was radiological objective response rate (ORR).
introduction
Aggressive surgical approaches to colorectal cancer (CRC) metastases are increasingly practised with a proportion of patients enjoying long-term survival. Five-year overall survival (OS) rates of 30%-40% are seen with resection of liver metastases [1] , despite a lack of randomised data to support surgery. Perioperative FOLFOX [oxaliplatin-infused 5-fluorouracil (5-FU)-leucovorin (LV)] has been accepted as a treatment strategy for resectable liver metastases based on the European Organisation for Research and Treatment of Cancer-40983 study showing a 3-year progression-free survival (PFS) benefit in the eligible and resected patient population [2] . Patients with unresectable CRC metastases are associated with a poor prognosis. With palliative combination chemotherapy, the 5-year survival rates with oxaliplatin-or irinotecan-based chemotherapy were reported to be <10% in patients with unresectable colorectal metastases [3] .
For patients who are considered ineligible for resection of liver metastases, a proportion of them would achieve sufficient downsizing after a period of conversion chemotherapy to allow liver resection. In one study, 13% of patients were converted from unresectable to resectable after an oxaliplatin-based chemotherapy [4] . This group of initially unresectable patients who had been converted to resectable had a respectable 5-year OS of 33%-42% [5, 6] and a 10-year OS of 27% [5] . Moreover, 15% of patients remained disease free at 10 years suggesting long-term cure [5] . These results compare favourably with patients who could only undergo palliative chemotherapy without potentially curative metastasectomy.
The rate of liver resection correlated significantly with objective response rates (ORRs) of neoadjuvant chemotherapy [7] . FOLFOXIRI (5-FU-LV-oxaliplatin-irinotecan) as well as the addition of cetuximab to FOLFOX or FOLFIRI (LV-5-FU-irinotecan) in Kras wild-type population resulted in a higher response rate compared with two-drug chemotherapy regimens [8] [9] [10] . These improved response rates led to an increased rate of surgical metastases resection. Bevacizumab did not significantly improve ORR when added to oxaliplatin-fluoropyrimidine compared with oxaliplatin or fluoropyrimidine alone [11] , and there were no statistically significant differences in resection rates in patients treated with bevacizumab compared with placebo [12] . Nevertheless, these are subgroup (post hoc) analyses nested in large randomised, controlled trials of unselected patients not limited to liver-only metastases.
As prospective bevacizumab data are lacking in this setting, we conducted a multicentre study of CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with high-risk colorectal liver-only metastases (CLMs) considered to be unsuitable for upfront liver resection in order to assess the efficacy and safety of this approach. In our BOXER (bevacizumab, oxaliplatin, xeloda in unresectable liver metastases) study, CAPOX plus bevacizumab was used as it was considered an accepted first-line treatment of advanced CRC [11, 13] , and high-risk disease was based on large size, poorly located, multinodular, and synchronous presentation of liver metastases [14] [15] [16] . 
patients and methods

patients selection
The eligibility criteria were as follows: histologically proven colorectal adenocarcinoma with poor-risk liver-only metastases; no previous chemotherapy for metastatic CRC; no evidence of extrahepatic metastatic disease on clinical examination, on computed tomography (CT) of chest, abdomen, and pelvis, and/or on PET; ‡18 years of age; World Health Organisation performance status (PS) of zero to two; and adequate haematological (white blood cell >3 · 10 9 /l, neutrophil >1.5 · 10 9 /l, platelet >100 · 10 9 /l), renal [serum creatinine level less than the upper limit of institutional normal range (ULN) or calculated creatinine clearance level >50 ml/min], and liver (serum bilirubin <1.5 · ULN, alanine aminotransferase and aspartate aminotransferase <5 · ULN) function. Before entry into the study, all patients were assessed by a multidisciplinary team (MDT) comprising medical, radiation, and surgical oncologists; gastroenterologists; and radiologists. Patients were considered to have poor-risk disease not deemed to be suitable for upfront resection if they had one or more of the following features: more than four metastases, any liver lesion with diameter >5 cm, location and distribution of metastatic disease within the liver unsuitable for resection with clear margins (e.g. involvement of both lobes of liver, invasion of intrahepatic vascular structures), extent of liver involvement precluding resection with adequate postresection residual liver parenchyma volume for viable liver function in the immediate postoperative period, and inability to retain adequate vascular inflow and outflow to maintain viable liver function. These patients were deemed to be technically unresectable according to previously published criteria [17] . In addition, patients were eligible if they presented with synchronous liver-only metastases diagnosed at the same time as the primary tumour, or liver metastases diagnosed during the first postoperative scan in patients who had had their primary tumour resected, as these patients also had poor prognosis, regardless of upfront resectability for liver metastases [15, 16] . If primary tumour was in situ, it had to be considered resectable with curative intent, whereas liver metastases could be resectable or unresectable. Additional eligibility criteria are detailed in Appendix 1 (available as supplementary data in Annals of Oncology online).
At baseline, all patients were required to have a CT scan of chest, abdomen, and pelvis; liver-specific contrast-enhanced (TESLA or Primovist) magnetic resonance imaging (MRI) of liver; and carcinoembryonic antigen measurement. PET scanning was recommended, but not mandatory for all patients to exclude extrahepatic disease. ) and bevacizumab (7.5 mg/kg) were administered i.v. on day 1 every 3 weeks. Capecitabine was given orally at a dose of 1700 mg/m 2 /day divided into two split doses for 14 days followed by 7 days' rest repeated every 3 weeks. Dose adjustment was made in the event of toxicity assessed according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0. Operability was reassessed every four cycles (12 weeks) with CT and MRI scans and this would then be rediscussed at liver MDT meetings. Nonprogressors who remained unresectable would proceed to a further four cycles of treatment.
surgery. Patients deemed to be resectable would undergo surgery at an 8-week interval from last dose of bevacizumab (6 weeks from last dose of chemotherapy). Patients with in situ primary tumours could have either synchronous or staged resection of primary tumour and liver metastases as per local practice.
postoperative chemotherapy. After recovery from surgery, patients received another 12 weeks of CAPOX plus bevacizumab at the same dose schedule as preoperative block.
evaluation of response
Radiological tumour response for liver metastases was measured using MRI and CT scans. Radiological tumour response was evaluated in accordance to the RECIST guidelines [18] . Best achieved ORR was reported as patients were scheduled to undergo surgical resection after assessment scans.
statistical considerations
This phase II study was designed using the optimal two-stage design with A'Hern exact P value [19] . The primary end point was the best achieved ORR, calculated as the sum of observed complete and partial responses. An ORR rate of 60% was considered acceptable (p1) and ORR rate of 40% would be ruled out as unacceptable (p0). In the first stage, if more than Annals of Oncology original article seven patients achieved an objective response of 16 patients, then the study would proceed to the second stage with a further 30 patients. If more than 23 patients responded of the total of 46 patients, then the treatment will be considered suitable for further evaluation (one-sided a = 0.05, 80% power).
PFS was calculated from the date of trial entry until disease progression, relapse, second colorectal primary, death from any cause, or censored at last follow-up. OS was calculated from the date of trial entry until death from any cause or censored at last follow-up. Both PFS and OS were estimated using the Kaplan-Meier method [20] . All analyses were carried out using SPSS package version 15 (SPSS Inc., Chicago, IL).
results
Between 26 June 2006 and 15 January 2009, 46 patients were recruited into the study. One patient was ineligible due to metachronous, resectable liver metastases. This patient was included in safety analysis but not in efficacy analyses. Table 1 shows the baseline characteristics. Although baseline PET scan was not mandated, 42 of 46 (91%) patients had baseline PET scans.
In the first stage of the study, 13 of 16 patients achieved a radiological response and thus we proceeded to the second stage of the study. Table 2 shows the best achieved radiological response for the entire study cohort. Objective responses were seen in 35 patients [78%; 95% confidence interval (CI) 63% to 89%]. Four (9%) patients achieved radiological complete response (CR) of liver metastases as determined by MRI. All four of these patients had also received capecitabine-based chemoradiation to their primary rectal tumour. To qualify for CR, patients had to have their primary tumour completely resected (n = 3) or in radiologically CR (n = 1). Of these four patients, three had resectable liver metastases, while the remaining one had more than four, thus unresectable metastases. As per the policy of our treating institutions, patients with radiological CR did not proceed to liver resection. Only one of these four patients relapsed with solitary liver metastasis after 23 months. He received percutaneous radiofrequency ablation (RFA) twice to further CR and maintained so at the last follow-up. The remaining three patients had sustained CR with a follow-up of 20, 18, and 18 months, respectively. Figure 1 shows the progress of all eligible patients during the trial. To date, 18 of 45 (40%) of the eligible patients have proceeded to liver metastasectomy. Additionally, five (11%) patients did not undergo hepatic resection because of radiological CR (n = 4) or no lesion found at laparotomy (n = 1). Twelve of 30 (40%) patients whose disease was considered to be initially unresectable at trial entry were converted to technically resectable after trial treatment.
With a median follow-up of 12.5 months, the 6-and 12-month PFS rates were 73% (95% CI 58% to 84%) and 50% (95% CI 34% to 64%), respectively, and the 6-and 12-month OS rates were 96% (95% CI 83% to 99%) and 86% (95% CI 70% to 94%), respectively. Figure 2 shows the PFS and OS for all eligible patients.
The median number of bevacizumab-containing cycles was eight. For those patients proceeding to liver resection, the median number of preoperative cycles of CAPOX plus bevacizumab delivered was four, with a range of three to nine. Of this latter group, 6 of 18 patients required a preoperative chemotherapy dose reduction (2 required capecitabine reduction, 2 required oxaliplatin dose reduction, and 2 required dose reduction of both agents). Nine patients also had capecitabine-based chemoradiation to the primary tumour and five patients underwent percutaneous RFA to their liver metastases while receiving active treatment within the study. The median time from last dose of bevacizumab to surgery was 10.8 weeks (range 7.3-26.7 weeks). Table 3 shows the grade 3-4 toxic effects encountered during chemotherapy. One patient changed from capecitabine to raltitrexed after one cycle due to grade 2 chest pain of uncertain origin. Postoperative events of interest included death, Objective tumour responses were seen in 78% of our patients, thus meeting the study's primary end point. Furthermore, 40% of patients with initially unresectable liver metastases were converted to technically resectable. Forty percent of our eligible patients underwent liver resection and an additional 11% of patients did not undergo hepatic resection because of radiological CR (n = 4) or no lesion found at laparotomy (n = 1), demonstrating favourable responses to neoadjuvant CAPOX plus bevacizumab. No new safety concerns were found in our study and postoperative complication rate was acceptable.
In the absence of universally accepted criteria regarding resectability of liver metastases, there remain institutional differences in the definition. This is further complicated by the increasing use of RFA procedures as an adjunct (or alternative) to liver resection [21] . Nevertheless, our study population represents a group of patients with liver-only metastases deemed by our MDT to be unsuitable to proceed to upfront resection, rather more appropriate for a neoadjuvant approach in an attempt to achieve downsizing (and possibly 'conversion' to resectable status) and/or to demonstrate in vivo sensitivity to the therapeutic agents used.
For patients with CRC liver metastases considered not suitable for upfront resection, the likelihood of response to therapy is one of the most important factors to consider when selecting the neoadjuvant regimen to allow adequate tumour downsizing and subsequent surgery. As our study was designed as a pragmatic trial, the imaging frequency of every 12 weeks was in line with the UK practice. This did highlight the responses seen in our study were durable with at least 12 weeks' duration. Interestingly, the ORR of 78% in our study
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is comparable with the response rate seen in another study of patients with unresectable CLMs [22] . In the CEtuximab in neoadjuvant treatment of non-resectable colorectal LIver Metastases (European Cancer Study) study, among the Kras wild-type population treated with FOLFIRI/FOLFOX plus cetuximab, the response rate was 70% [22] . Although the entry criteria differed between the BOXER and CELIM studies, and therefore direct comparison of the studies should only be done with caution, a similar number of patients recruited proceeded to liver surgery (BOXER and CELIM 40%) and a similar number of initially technically unresectable patients proceeded to liver resection (BOXER 27%; CELIM 28%). Additionally, four patients in our BOXER study achieved radiological CR and did not proceed to surgery. Since all four patients who had a CR in their liver also received long-course capecitabine-based chemoradiation, perhaps the additional systemic therapy contributed to the CR. Only one of these four patients relapsed with solitary liver metastasis after 23 months. The CELIM study did not report CR separately from partial response and there were no comments of whether all (if any) complete responders proceeded to surgery [22] . Of the 30 initially technically unresectable patients in our study, 12 (40%) were considered potentially suitable for resection on review of post-treatment imaging. Although the high response rate may be due to metastatic disease being limited to the liver and the overall good PS of the patient population, we previously reported an ORR of 59% with CAPOX alone in a similar patient population [23] , identical to a previous study [17] . This suggests that bevacizumab may contribute, at least in part, to an improved response rate, although given the caveats of cross-trial comparison. Furthermore, the conversion from initially unresectable to potentially suitable for resection could be subject to much controversy as this definition of conversion varies among different institutions. Nevertheless, the majority of our patients (41 of 46) were recruited at Royal Marsden Hospital and post-treatment imaging was reviewed again at our liver MDT under the auspice of two liver surgeons (SM and AK) during the study period; thus, decision making on resectability was relatively uniform. original article
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Twenty percent of our patients had an R0 resection and an additional 13% had an R1 resection. Therefore, 33% of eligible patients had all macroscopic disease resected. However, due to vascular proximity or multinodularity, sometimes complete macroscopic clearance could only be achieved through an R1 resection. With effective perioperative chemotherapy, the prognostic significance of an R0 resection is less clear. A recent series showed no significant differences in disease-free survival or OS in patients who had R0 versus R1 resections [24] . An expert panel on behalf of the European Colorectal Metastases Treatment Group concluded that where possible it was better to remove a metastasis than to leave it in situ and that going forward R1 resections may be an acceptable clinical strategy provided that they confer meaningful patient benefit [14] . Interestingly in the CELIM study, 46% of patients had an R0 or R1 resection and/or RFA [22] , whereas for our BOXER study, 44% had an R0 or R1 resection or achieved complete radiological response. However, one also noted that 38% of R0/R1 resection rate could also be achieved with FOLFOX alone without biological agents [17] , although in this study, one of the unresectability criteria was bilobar disease-not regarded as a sole unresectable criterion by liver surgeons nowadays.
Pathological response to neoadjuvant chemotherapy in liver metastases has been shown to correlate with improved survival [25, 26] . Bevacizumab in combination with oxaliplatin/fluoropyrimidines was associated with the highest major pathological response rate [26] . Noninvasive CT morphological criteria had also recently been developed that correlated the CT appearances of liver metastases after bevacizumab treatment with pathological response and OS [27] . These CT morphological response and pathological response criteria could potentially be incorporated in future clinical trials as surrogate markers for survival outcome and expedite novel drug development in treatment of CRC liver metastases.
As we move into the era of tailored therapy, predictive biomarkers must also be considered. Recruitment to the CELIM study pre-dated knowledge regarding lack of efficacy for cetuximab in Kras mutated patients; therefore, only 71% of patients recruited had wild-type Kras. Data continue to emerge, although not always consistent, regarding other predictive biomarkers for epidermal growth factor receptor (EGFR) inhibitors, but the majority are markers of nonresponse rather than of guaranteed response [28] . To date, no predictive biomarkers for bevacizumab have been identified. We have obtained scientific and ethical committee approval to collect and analyse tissue from patients treated within the BOXER and our previous study [23] . Thus, we shall have parallel patient groups (although not randomised) treated with CAPOX with or without bevacizumab in a similar patient population of liver-only CRC metastasis unsuitable for upfront resection. Apart from identifying potential biomarkers, we are planning to correlate pathological response as well as CT morphological response as discussed previously and report these data in a subsequent publication. Nevertheless, as bevacizumab is of benefit in both Kras wild-type and mutant patient population [29] , in the absence of contraindications, bevacizumab plus chemotherapy could be commenced without delay, compared with waiting for Kras mutational analysis, as would be necessary for EGFR-targeted antibody.
An important component in our trial that deserves emphasis is the coordinated multidisciplinary team approach that was essential for modern care in patients with CRC liver metastasis. The majority (59%) of our patients still had primary tumour in situ at trial registration, many of whom had locally advanced synchronous rectal cancer. Although not specified in the protocol, the exact sequence of chemotherapy, radiotherapy, and resection of either liver or primary tumour required much attention by the MDT and this continued to evolve during our trial.
CAPOX plus bevacizumab was generally well tolerated, which was not unexpected given the phase III data that emerged from the NO16966 trial and the subsequent acceptance of the regimen as a first-line treatment option in many countries [11] . For those proceeding to liver resection, with a median time of 10.8 weeks between last dose of bevacizumab and liver surgery, there were a few perioperative complications. These results are consistent with other published studies [12, 30, 31] . One notable eligibility difference between BOXER and CELIM was that patients enrolled into CELIM were required to have their primary CRC removed before study entry, whereas 59% of our patients still had their primary tumour in situ at the time of trial registration. As primary tumour in situ had been found to have a higher risk of gastrointestinal perforation [32, 33] , it was reassuring that only one patient developed duodenal perforation during postoperative chemotherapy after primary CRC and liver resection. Together, these data would help to alleviate initial anxieties regarding surgery and perioperative risk in the era of vascular endothelial growth factor inhibitors.
In conclusion, this is the first reported prospective study evaluating CAPOX plus bevacizumab in patients with CLMs not selected for upfront resection. The efficacy of this combination regimen resulted in high radiological response rate of 78% and conversion rate of 40% from initially unresectable to resectable metastases. This combination is not confined to Kras wild-type patient population and, together with its safety, could be considered as a neoadjuvant treatment option for patients with high-risk liver-only metastases not selected for upfront liver resection. Annals of Oncology original article disclosure RW has received honorarium and served on the advisory board for Roche; DC has served on uncompensated advisory boards for Roche and Sanofi-Aventis and received research funding from Roche and Sanofi-Aventis; TH has received honorarium and served on the advisory board for Roche and Sanofi-Aventis; SM has served on the advisory board for Roche; YJC has received honorarium from Roche and Sanofi-Aventis; and IC has received honoraria from Roche and Sanofi-Aventis, served on the advisory board for Roche, and received research funding from Roche. All remaining authors have declared no conflicts of interest.
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